arginyl-glycyl-aspartic acid has been researched along with Fabry Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abasolo, I; Cámara-Sánchez, P; Corchero, JL; Córdoba, A; Cristóbal-Lecina, E; Danino, D; Díaz-Riascos, ZV; García-Aranda, N; González-Mira, E; González-Rioja, R; Ionita, I; Lyngsø, J; Merlo-Mas, J; Nedergaard Pedersen, J; Passemard, S; Pedersen, JS; Portnaya, I; Pulido, D; Royo, M; Sala, S; Schwartz, S; Tomsen-Melero, J; Veciana, J; Ventosa, N | 1 |
1 other study(ies) available for arginyl-glycyl-aspartic acid and Fabry Disease
| Article | Year |
|---|---|
Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment.
Topics: alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Humans; Nanostructures; Oligopeptides; Particle Size; Surface Properties; Surface-Active Agents | 2021 |